Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retinal stem cell therapy - jCyte

Next Previous
Search
Drug Profile

Retinal stem cell therapy - jCyte

Alternative Names: hRPC - jCyte; Human retinal progenitor cell therapy - jCyte; Human retinal progenitor cells - jCyte; jCell; jCell therapy - jCyte

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator jCyte
  • Developer California Institute for Regenerative Medicine; jCyte
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa
  • Preclinical Diabetic retinopathy; Dystrophy; Glaucoma; Optic nerve disorders

Most Recent Events

  • 06 Apr 2025 jCyte initiates a phase II trial in retinitis pigmentosa in USA (Intravitreous, Injection) (NCT06912633)
  • 21 Feb 2024 US FDA reviews the planned phase II/III tria l design and approves the primary endpoint and the two jCell doses to be included in the trial
  • 21 Feb 2024 jCyte plans a phase II/III pivotal trial for Retinitis pigmentosa (Intravitreous) in second half of 2024

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top